Contraceptive Technology Update – October 1, 2012
October 1, 2012
View Issues
-
LARC use sees substantial increase — How to boost use in women at risk
Good news: More women are choosing long-acting reversible contraceptives (LARC methods) such as the intrauterine device (IUD) and the contraceptive implant. -
Oral drug no longer first-line for gonorrhea
Update your practice: The Centers for Disease Control and Prevention (CDC) no longer recommends the oral antibiotic cefixime as a first-line treatment option for gonorrhea due to possible drug resistance. -
Check interim guidance for PrEP in men, women
The Centers for Disease Control and Prevention (CDC) has issued new interim guidance for use of pre-exposure prophylaxis (PrEP) for in heterosexual men and women at high risk for HIV. -
Dapivirine vaginal ring eyed for HIV prevention
Two sister studies have been launched in Africa to evaluate the ability of a new monthly vaginal ring containing the antiretroviral drug dapivirine to safely prevent new HIV infections in women. -
Herd protection seen with HPV immunization
Findings from a just-published study of young women ages 13-16 in Cincinnati are the first to document herd protection after introduction of the human papillomavirus (HPV) vaccine. -
Hormone therapy focus of new joint statement
The North American Menopause Society, the American Society for Reproductive Medicine, and The Endocrine Society have issued a joint statement concluding that hormone therapy (HT) is still an acceptable treatment for menopausal symptoms.